Decoding 11 Analyst Evaluations For Jazz Pharmaceuticals
Decoding 11 Analyst Evaluations For Jazz Pharmaceuticals
破解11位分析師對爵士製藥的評估
Throughout the last three months, 11 analysts have evaluated Jazz Pharmaceuticals (NASDAQ:JAZZ), offering a diverse set of opinions from bullish to bearish.
在過去的三個月裏，11名分析師針對Jazz Pharmaceuticals（納斯達克代碼：JAZZ）進行了評估，提出了從看好到看淡不一的不同觀點。
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
下表提供了他們最近的評級快照，展示了情緒在過去30天中的演變情況，並將其與之前的月份進行比較。
In the assessment of 12-month price targets, analysts unveil insights for Jazz Pharmaceuticals, presenting an average target of $163.73, a high estimate of $210.00, and a low estimate of $113.00. A 4.25% drop is evident in the current average compared to the previous average price target of $171.00.
在對12個月價格目標的評估中，分析師揭示了針對 Jazz Pharmaceuticals 的見解，呈現出一個平均目標價格爲163.73美元，一個最高估價爲210美元和一個最低估價爲113美元。與先前的平均目標價格171.00美元相比，目前平均目標呈4.25％下降。
Analyzing Analyst Ratings: A Detailed Breakdown
分析分析師評級：詳細剖析
A comprehensive examination...
最近的...
登入免費觀看全文
登入/註冊